Cancer Trials Support Unit

Solicitation75N91021R00021Notice typeAward Notice

Attachments

0 files

No attachments available.

Version History

Cancer Trials Support Unit

Award75N91021R00021Jul 28, 2022 · v5

LatestViewing

Cancer Trials Support Unit

Solicitation75N91021R00021Oct 21, 2021 · v4

Cancer Trials Support Unit

Award75N91021R00021Jul 28, 2022 · v2

Opportunity Summary

The National Institutes of Health, National Cancer Institute, awarded an Indefinite Delivery, Indefinite Quantity (IDIQ) contract to support the Cancer Trials Support Unit (CTSU) under solicitation number 75N91021R00021. This award carries a maximum potential value of $548,000,000 if all options are exercised. The scope includes Task Area 1 for project kick-off and transition activities, as well as Task Area 3 for awareness, education, and training. Performance is designated for the United States under the primary point of contact Chris Shih.

The contract is classified under NAICS 541715 for Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) and PSC AN13 for Health R&D Services, Health Care Services, and Experimental Development. The award metadata identifies a SBP set-aside. Recorded under contract number 75N91022D00013, this notice was officially published and updated on July 28, 2022.

Generated by Lumen AI

Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.

Opportunity Summary

Opportunity Details

Response deadline: —No deadline provided
NAICS: 541715 (opens in new tab)
PSC: AN13 (opens in new tab)
Set aside: SBP
Published: Jul 28, 2022
Updated: Jul 28, 2022
Agency: NATIONAL INSTITUTES OF HEALTH (opens in new tab)
Office: NIH NCI
Department: —
Source: View on SAM.gov (opens in new tab)

Contact and place of performance

Point of contact: Chris Shih

Place of performance: USA

Original Description

Contract Title: Cancer Trials Support Unit (CTSU) The IDIQ contract number 75N91022D00013 was awarded against solicitation number 75N91021R00021. The maximum value of the IDIQ contract is $548,000,000 if all options are exercised. Task Areas Awarded: Task Area 1: Project Kick-off Meeting/Transition Activities Task Area 3: Awareness, Education, and Training (AET)

NAICS 541715 award landscapeCompare incumbent and competitor award activity

Open PSC AN13 opportunitiesTrack solicitations in this service category

PSC AN13 contractsReview related contracts in this category

Opportunity Summary

The National Institutes of Health, National Cancer Institute, awarded an Indefinite Delivery, Indefinite Quantity (IDIQ) contract to support the Cancer Trials Support Unit (CTSU) under solicitation number 75N91021R00021. This award carries a maximum potential value of $548,000,000 if all options are exercised. The scope includes Task Area 1 for project kick-off and transition activities, as well as Task Area 3 for awareness, education, and training. Performance is designated for the United States under the primary point of contact Chris Shih.

The contract is classified under NAICS 541715 for Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) and PSC AN13 for Health R&D Services, Health Care Services, and Experimental Development. The award metadata identifies a SBP set-aside. Recorded under contract number 75N91022D00013, this notice was officially published and updated on July 28, 2022.

Generated by Lumen AI

Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.